0	28	Calcium/calmodulin-dependent	calcium/calmodulin-dependent	JJ
29	36	protein	protein	NN
37	43	kinase	kinase	NNP
44	46	II	ii	CD
47	60	downregulates	downregulate	VBZ
61	65	both	both	CC
66	77	calcineurin	calcineurin	NN
78	81	and	and	CC
82	89	protein	protein	NN
90	96	kinase	kinase	NNP
97	107	C-mediated	c-mediated	JJ
108	116	pathways	pathway	NNS
117	120	for	for	IN
121	129	cytokine	cytokine	NN
130	134	gene	gene	NN
135	148	transcription	transcription	NN
149	151	in	in	IN
152	157	human	human	JJ
158	159	T	t	NN
160	165	cells	cell	NNS
165	166	.	.	.

168	178	Engagement	engagement	NN
179	181	of	of	IN
182	185	the	the	DT
186	187	T	t	NN
188	192	cell	cell	NN
193	201	receptor	receptor	NN
202	205	for	for	IN
206	213	antigen	antigen	NN
214	223	activates	activate	VBZ
224	237	phospholipase	phospholipase	NN
238	239	C	C	NNP
240	249	resulting	result	VBG
250	252	in	in	IN
253	255	an	an	DT
256	264	increase	increase	NN
265	267	in	in	IN
268	281	intracellular	intracellular	JJ
282	286	free	free	JJ
287	294	calcium	calcium	NN
295	308	concentration	concentration	NN
309	310	(	(	(
310	311	[	[	(
311	317	Ca2+]i	ca2+]i	NN
317	318	)	)	)
319	322	and	and	CC
323	333	activation	activation	NN
334	336	of	of	IN
337	344	protein	protein	NN
345	351	kinase	kinase	NNP
352	353	C	C	NNP
354	355	(	(	(
355	358	PKC	PKC	NNP
358	359	)	)	)
359	360	.	.	.

361	370	Increased	increase	VBN
371	372	[	[	(
372	378	Ca2+]i	Ca2+]i	NNP
379	388	activates	activate	VBZ
389	414	Ca2+/calmodulin-dependent	ca2+/calmodulin-dependent	JJ
415	422	kinases	kinase	NNS
423	432	including	include	VBG
433	436	the	the	DT
437	452	multifunctional	multifunctional	JJ
453	478	Ca2+/calmodulin-dependent	ca2+/calmodulin-dependent	JJ
479	486	protein	protein	NN
487	493	kinase	kinase	NNP
494	496	II	ii	CD
497	498	(	(	(
498	503	CaM-K	CaM-K	NNP
504	506	II	ii	CD
506	507	)	)	)
507	508	,	,	,
509	511	as	as	RB
512	516	well	well	RB
517	519	as	as	IN
520	531	calcineurin	calcineurin	NN
531	532	,	,	,
533	534	a	a	DT
535	539	type	type	NN
540	542	2B	2b	NN
543	550	protein	protein	NN
551	562	phosphatase	phosphatase	NN
562	563	.	.	.

564	570	Recent	recent	JJ
571	578	studies	study	NNS
579	583	have	have	VBP
584	594	identified	identify	VBN
595	606	calcineurin	calcineurin	NN
607	609	as	as	IN
610	611	a	a	DT
612	615	key	key	JJ
616	622	enzyme	enzyme	NN
623	626	for	for	IN
627	638	interleukin	interleukin	NN
639	640	(	(	(
640	645	IL)-2	il)-2	NN
646	649	and	and	CC
650	654	IL-4	il-4	NN
655	663	promoter	promoter	NN
664	674	activation	activation	NN
674	675	.	.	.

676	683	However	however	RB
683	684	,	,	,
685	688	the	the	DT
689	693	role	role	NN
694	696	of	of	IN
697	702	CaM-K	CaM-K	NNP
703	705	II	ii	CD
706	713	remains	remain	VBZ
714	721	unknown	unknown	JJ
721	722	.	.	.

723	725	We	we	PRP
726	730	have	have	VBP
731	735	used	use	VBN
736	743	mutants	mutant	NNS
744	746	of	of	IN
747	752	these	these	DT
753	760	kinases	kinase	NNS
761	764	and	and	CC
765	777	phosphatases	phosphatas	NNS
778	779	(	(	(
779	784	gamma	gamma	NN
785	792	B*CaM-K	b*cam-k	NN
793	796	and	and	CC
797	802	delta	delta	NN
803	809	CaM-AI	CaM-AI	NNP
809	810	,	,	,
811	823	respectively	respectively	RB
823	824	)	)	)
825	827	to	to	TO
828	835	explore	explore	VB
836	841	their	their	PRP$
842	850	relative	relative	JJ
851	855	role	role	NN
856	858	in	in	IN
859	867	cytokine	cytokine	NN
868	872	gene	gene	NN
873	886	transcription	transcription	NN
887	890	and	and	CC
891	896	their	their	PRP$
897	909	interactions	interaction	NNS
910	914	with	with	IN
915	928	PKC-dependent	pkc-dependent	JJ
929	938	signaling	signaling	NN
939	947	systems.	systems.	NN
948	953	gamma	gamma	NN
954	961	B*CaM-K	b*cam-k	NN
962	965	and	and	CC
966	971	delta	delta	NN
972	978	CaM-AI	CaM-AI	NNP
978	979	,	,	,
980	985	known	know	VBN
986	988	to	to	TO
989	996	exhibit	exhibit	VB
997	1009	constitutive	constitutive	JJ
1010	1028	Ca(2+)-independent	ca(2+)-independent	JJ
1029	1037	activity	activity	NN
1037	1038	,	,	,
1039	1043	were	be	VBD
1044	1057	cotransfected	cotransfecte	VBN
1058	1059	(	(	(
1059	1064	alone	alone	RB
1065	1067	or	or	CC
1068	1070	in	in	IN
1071	1082	combination	combination	NN
1082	1083	)	)	)
1084	1086	in	in	IN
1087	1093	Jurkat	Jurkat	NNP
1094	1095	T	t	NN
1096	1101	cells	cell	NNS
1102	1106	with	with	IN
1107	1108	a	a	DT
1109	1116	plasmid	plasmid	NN
1117	1127	containing	contain	VBG
1128	1131	the	the	DT
1132	1138	intact	intact	JJ
1139	1143	IL-2	il-2	NN
1144	1152	promoter	promoter	NN
1153	1160	driving	drive	VBG
1161	1164	the	the	DT
1165	1175	expression	expression	NN
1176	1178	of	of	IN
1179	1182	the	the	DT
1183	1198	chloramphenicol	chloramphenicol	NN
1199	1216	acetyltransferase	acetyltransferase	NN
1217	1225	reporter	reporter	NN
1226	1230	gene	gene	NN
1230	1231	.	.	.

1232	1246	Cotransfection	cotransfection	NN
1247	1249	of	of	IN
1250	1255	gamma	gamma	NN
1256	1263	B*CaM-K	b*cam-k	NN
1264	1268	with	with	IN
1269	1272	the	the	DT
1273	1277	IL-2	il-2	NN
1278	1286	promoter	promoter	NN
1287	1296	construct	construct	NN
1297	1310	downregulated	downregulate	VBD
1311	1314	its	its	PRP$
1315	1328	transcription	transcription	NN
1329	1331	in	in	IN
1332	1340	response	response	NN
1341	1343	to	to	TO
1344	1355	stimulation	stimulation	NN
1356	1360	with	with	IN
1361	1370	ionomycin	ionomycin	NN
1371	1374	and	and	CC
1375	1382	phorbol	phorbol	NN
1383	1392	myristate	myristate	NN
1393	1400	acetate	acetate	NN
1401	1402	(	(	(
1402	1405	PMA	PMA	NNP
1405	1406	)	)	)
1406	1407	.	.	.

1408	1411	The	the	DT
1412	1422	inhibitory	inhibitory	JJ
1423	1429	effect	effect	NN
1430	1432	of	of	IN
1433	1438	CaM-K	CaM-K	NNP
1439	1441	II	ii	CD
1442	1444	on	on	IN
1445	1449	IL-2	il-2	NN
1450	1458	promoter	promoter	NN
1459	1462	was	be	VBD
1463	1473	associated	associate	VBN
1474	1478	with	with	IN
1479	1488	decreased	decrease	VBN
1489	1502	transcription	transcription	NN
1503	1505	of	of	IN
1506	1509	its	its	PRP$
1510	1514	AP-1	ap-1	NN
1515	1518	and	and	CC
1519	1524	NF-AT	nf-at	NN
1525	1540	transactivating	transactivating	NN
1541	1549	pathways	pathway	NNS
1549	1550	.	.	.

1551	1556	Under	under	IN
1557	1560	the	the	DT
1561	1565	same	same	JJ
1566	1576	conditions	condition	NNS
1576	1577	,	,	,
1578	1583	delta	delta	NN
1584	1590	CaM-AI	CaM-AI	NNP
1591	1603	superinduced	superinduce	VBD
1604	1608	IL-2	il-2	NN
1609	1617	promoter	promoter	NN
1618	1626	activity	activity	NN
1627	1628	(	(	(
1628	1641	approximately	approximately	RB
1642	1649	twofold	twofold	JJ
1650	1658	increase	increase	NN
1658	1659	)	)	)
1659	1660	.	.	.

1661	1665	When	when	WRB
1666	1670	both	both	DT
1671	1678	mutants	mutant	NNS
1679	1683	were	be	VBD
1684	1688	used	use	VBN
1689	1691	in	in	IN
1692	1703	combination	combination	NN
1703	1704	,	,	,
1705	1710	gamma	gamma	NN
1711	1718	B*CaM-K	b*cam-k	NN
1719	1728	inhibited	inhibit	VBD
1729	1732	the	the	DT
1733	1742	induction	induction	NN
1743	1745	of	of	IN
1746	1749	the	the	DT
1750	1754	IL-2	il-2	NN
1755	1763	promoter	promoter	NN
1764	1766	by	by	IN
1767	1772	delta	delta	NN
1773	1779	CaM-AI	CaM-AI	NNP
1779	1780	.	.	.

1781	1788	Similar	similar	JJ
1789	1796	results	result	NNS
1797	1801	were	be	VBD
1802	1810	obtained	obtain	VBN
1811	1815	when	when	WRB
1816	1817	a	a	DT
1818	1827	construct	construct	NN
1828	1838	containing	contain	VBG
1839	1842	the	the	DT
1843	1847	IL-4	il-4	NN
1848	1856	promoter	promoter	NN
1857	1861	also	also	RB
1862	1865	was	be	VBD
1866	1871	used.	used.	JJ
1872	1877	gamma	gamma	NN
1878	1885	B*CaM-K	b*cam-k	NN
1886	1890	also	also	RB
1891	1904	downregulated	downregulate	VBD
1905	1908	the	the	DT
1909	1919	activation	activation	NN
1920	1922	of	of	IN
1923	1927	AP-1	ap-1	NN
1928	1930	in	in	IN
1931	1939	response	response	NN
1940	1942	to	to	TO
1943	1955	transfection	transfection	NN
1956	1960	with	with	IN
1961	1962	a	a	DT
1963	1977	constitutively	constitutively	RB
1978	1984	active	active	JJ
1985	1991	mutant	mutant	NN
1992	1994	of	of	IN
1995	1998	PKC	PKC	NNP
1999	2001	or	or	CC
2002	2013	stimulation	stimulation	NN
2014	2018	with	with	IN
2019	2022	PMA	PMA	NNP
2022	2023	.	.	.

2024	2029	These	these	DT
2030	2037	results	result	NNS
2038	2045	suggest	suggest	VBP
2046	2050	that	that	IN
2051	2056	CaM-K	CaM-K	NNP
2057	2059	II	ii	CD
2060	2063	may	may	MD
2064	2069	exert	exert	VB
2070	2078	negative	negative	JJ
2079	2089	influences	influence	NNS
2090	2092	on	on	IN
2093	2101	cytokine	cytokine	NN
2102	2106	gene	gene	NN
2107	2120	transcription	transcription	NN
2121	2123	in	in	IN
2124	2129	human	human	JJ
2130	2131	T	t	NN
2132	2137	cells	cell	NNS
2137	2138	,	,	,
2139	2142	and	and	CC
2143	2150	provide	provide	VB
2151	2162	preliminary	preliminary	JJ
2163	2171	evidence	evidence	NN
2172	2175	for	for	IN
2176	2184	negative	negative	JJ
2185	2195	cross-talk	cross-talk	NN
2196	2200	with	with	IN
2201	2204	the	the	DT
2205	2217	calcineurin-	calcineurin-	NN
2218	2221	and	and	CC
2222	2226	PKC-	pkc-	NN
2227	2236	dependent	dependent	JJ
2237	2246	signaling	signaling	NN
2247	2254	systems	system	NNS
2254	2255	.	.	.